PL3810279T3 - Kombinacja obejmująca użycie związku oligopeptydowego i przeciwciała anty-pd-1 lub pd-l1 do stosowania w leczeniu chorób nowotworowych - Google Patents

Kombinacja obejmująca użycie związku oligopeptydowego i przeciwciała anty-pd-1 lub pd-l1 do stosowania w leczeniu chorób nowotworowych

Info

Publication number
PL3810279T3
PL3810279T3 PL19734322.1T PL19734322T PL3810279T3 PL 3810279 T3 PL3810279 T3 PL 3810279T3 PL 19734322 T PL19734322 T PL 19734322T PL 3810279 T3 PL3810279 T3 PL 3810279T3
Authority
PL
Poland
Prior art keywords
antibody
combination
neoplastic conditions
treating neoplastic
oligopeptidic compound
Prior art date
Application number
PL19734322.1T
Other languages
English (en)
Inventor
Lars Prestegarden
Original Assignee
Cytovation ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovation ASA filed Critical Cytovation ASA
Publication of PL3810279T3 publication Critical patent/PL3810279T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL19734322.1T 2018-06-19 2019-06-19 Kombinacja obejmująca użycie związku oligopeptydowego i przeciwciała anty-pd-1 lub pd-l1 do stosowania w leczeniu chorób nowotworowych PL3810279T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810058.6A GB201810058D0 (en) 2018-06-19 2018-06-19 Combination therapy using a peptide
PCT/EP2019/066295 WO2019243471A1 (en) 2018-06-19 2019-06-19 Combination therapy using a peptide

Publications (1)

Publication Number Publication Date
PL3810279T3 true PL3810279T3 (pl) 2024-02-26

Family

ID=63042825

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19734322.1T PL3810279T3 (pl) 2018-06-19 2019-06-19 Kombinacja obejmująca użycie związku oligopeptydowego i przeciwciała anty-pd-1 lub pd-l1 do stosowania w leczeniu chorób nowotworowych

Country Status (13)

Country Link
US (1) US20210154268A1 (pl)
EP (1) EP3810279B1 (pl)
JP (1) JP7525408B2 (pl)
KR (1) KR102783033B1 (pl)
CN (1) CN112566699B (pl)
AU (1) AU2019291079B2 (pl)
DK (1) DK3810279T5 (pl)
ES (1) ES2960783T3 (pl)
GB (1) GB201810058D0 (pl)
IL (1) IL279461B2 (pl)
PL (1) PL3810279T3 (pl)
SG (1) SG11202012768XA (pl)
WO (1) WO2019243471A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270743B2 (en) 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
GB202000167D0 (en) * 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions
KR20260079600A (ko) * 2023-09-26 2026-06-02 사이토베이션 에이에스에이 β-카테닌과 연관된 암 치료

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201001602D0 (en) * 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
KR20160079114A (ko) * 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
WO2016207646A1 (en) * 2015-06-24 2016-12-29 Immodulon Therapeutics Limited A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy
EP3429618B1 (en) * 2016-03-16 2024-02-21 Amal Therapeutics SA Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine

Also Published As

Publication number Publication date
CN112566699A (zh) 2021-03-26
JP7525408B2 (ja) 2024-07-30
ES2960783T3 (es) 2024-03-06
AU2019291079B2 (en) 2025-12-18
IL279461B1 (en) 2025-12-01
KR102783033B1 (ko) 2025-03-18
DK3810279T3 (da) 2023-10-23
EP3810279A1 (en) 2021-04-28
SG11202012768XA (en) 2021-01-28
EP3810279B1 (en) 2023-09-13
WO2019243471A1 (en) 2019-12-26
GB201810058D0 (en) 2018-08-08
CA3103905A1 (en) 2019-12-26
NZ771705A (en) 2025-10-31
IL279461B2 (en) 2026-04-01
JP2021527677A (ja) 2021-10-14
KR20210022669A (ko) 2021-03-03
AU2019291079A1 (en) 2021-01-28
CN112566699B (zh) 2024-07-05
US20210154268A1 (en) 2021-05-27
DK3810279T5 (da) 2024-08-19
IL279461A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
IL276872A (en) Dosage for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
IL279455A (en) ANTI-PD-1 antibodies and their uses
IL266424B1 (en) A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma
IL274438A (en) Single-region antibodies against PD-L1 and their variants
IL285734A (en) Devices and methods for treating edema
SG11202012137UA (en) Methods for treating cancer with bispecific anti-cd3xmuc16 antibodies and anti-pd-1 antibodies
EP3716165A4 (en) ESG CRITERIA-BASED COMPANY EVALUATION DEVICE AND OPERATING PROCEDURES FOR IT
GB201805963D0 (en) PD-L1 Binding Affirmers and Uses Related Thereto
SG11202103221QA (en) Anti pd-l1 antibody and use thereof
EP3901172A4 (en) HUMANIZED ANTI-PD-1 ANTIBODIES AND THEIR USE
ZA202004907B (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
SMT202400528T1 (it) Benzopirrolo sostituito e inibitori del complemento strutturalmente correlati
PT4082570T (pt) Anticorpo anti-ctla-4 e a sua utilização
ZA202006255B (en) Anti-pd-l1 antibody and use thereof
IL276675A (en) Anti-PD-1 antibodies and uses thereof
IL283180A (en) Anti-PD-1 antibodies and their uses
EP3781201B8 (en) Antibodies for chelated radionuclides and clearing agents
IL292198A (en) Tim-3 inhibitors and their uses
HRP20260007T1 (hr) Humanizirano antitijelo protiv il17a i njegova uporaba
IL285569A (en) Anti-pd-l1 antibody and use thereof
SG11202111188VA (en) Anti-cd40 antibody and use thereof
SG11202103589XA (en) Materials and methods for treating cancer
SG11202103185XA (en) Systems and methods for use in handling components
IL287008A (en) Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
IL288692A (en) A bispecific antibody against a-syn/igf1r and its use